Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Center, Long-Term Immunogenicity Follow-Up Study of the GVGH altSonflex1-2-3 Shigella Vaccine 1, 2 and 3 Years After Vaccination in African Children

NCT07320716 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07320716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07320716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Center, Long-Term Immunogenicity Follow-Up Study of the GVGH altSonflex1-2-3 Shigella Vaccine 1, 2 and 3 Years After Vaccination in African Children
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 2, 2026
Completion date
October 31, 2028
Enrollment
528 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhoea